Skip to main content
. Author manuscript; available in PMC: 2015 Jun 14.
Published in final edited form as: Pharm Pat Anal. 2014 Jul;3(4):429–447. doi: 10.4155/ppa.14.22

Table 3.

The development of drugs to prevent Aβ aggregation.

Compounds Chemical class Assignee Patent number Phases Ref.
Tramiprosate Amidosulphuric acid Bellus Health, Inc., Canada WO054485A1(2010) Phase III [85]
Scyllo-Inositol Scyllitol Elan Pharmaceuticals, USA WO173808A1(2012) Phase II [86]
PBT1 Hydroxyquinoline derivatives Prana Biotechnology, Ltd, Australia WO074068A1(2008) Phase II [87]
PBT2 Hydroxyquinolines derivatives Prana Biotechnology, Ltd, Australia WO071944A1(2010) Phase II [88]
Epigallocate-chin-3-gallate Catechin Max-Delbruck-Centrum FurMolekulare Medizin, Germany US0117040A1(2009) Phase I [89]
7a Apomorphine derivatives Cytokine Pharmasciences, Inc., USA US20080096909 A1 Discovery [82]
8a Peptidomimetic derivatives Almqvist Fredrik, Sweden WO 2009134203 A1 Discovery [83]
9a Heterocyclic compounds Neuropore Therapies, Inc., USA WO2013134371 A1 Discovery [84]